MyChesCo on MSN2h
FDA Grants Fast Track Designation to PleoPharma’s PP-01 for Cannabis Withdrawal Syndrome
PleoPharma, Inc. has announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to PP-01, ...
FDA Grants Fast-Track Designation To Cannabis Withdrawal Syndrome Drug
U.S.-based PleoPharma announced yesterday that the FDA has granted it a fast-track designation for PP-01, a new ...
FDA warns users of popular weight-loss drugs to watch for counterfeits
Health experts say popular weight-loss drugs like Ozempic and Wegovy are safe, but the FDA warns counterfeits are becoming more widespread.
The Bakersfield Californian19d
Medimaps Breaks New Ground in Fracture Risk Assessment with FDA Clearance and MDR Certification for TBS Osteo Next Generation Software
medimaps group S.A., a global leader in AI-driven bone microarchitecture imaging solutions, proudly announces 510(k) clearance from FDA and MDR certification in EU for the latest version of its ...
Yahoo Finance19d
Medimaps Breaks New Ground in Fracture Risk Assessment with FDA Clearance and MDR Certification for TBS Osteo Next Generation Software
GENEVA, January 27, 2025--(BUSINESS WIRE)--medimaps group S.A., a global leader in AI-driven bone microarchitecture imaging solutions, proudly announces 510(k) clearance from FDA and MDR certification ...
Business Wire22d
Global Drug Safety & Pharmacovigilance Regulatory Requirements and Certification Training Course with Focus on EU and US (ONLINE EVENT: February 12, 2025 / ON-DEMAND ...
DUBLIN--(BUSINESS WIRE)--The "Global Regulatory Requirements for Drug Safety & Pharmacovigilance Certification Program" training has been added to ResearchAndMarkets.com's offering. This training ...
NBC News23d
Federal regulations paused, halting FDA's proposed ban on formaldehyde in hair products
The Food and Drug Administration announced it would decide by April 2024 whether chemical hair straightening products sold in the U.S. would be banned from using formaldehyde or ingredients that ...
CNN24d
FDA approves standalone use of J&J’s ketamine-derived depression treatment
The U.S. Food and Drug Administration expanded approval for Johnson & Johnson’s nasal spray, Spravato, to allow it to be used as a standalone treatment for patients with severe depression ...
Popular Science24d
FDA approves first-of-its-kind nasal spray for severe depression
Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the standalone treatment of major depressive disorder (MDD), PTSD ...
UPI24d
FDA approves Spravato, first monotherapy nasal spray to treat depression
Jan. 21 (UPI) --The Food and Drug Administration has approved the first-ever stand-alone nasal spray to treat drug-resistant depression. Johnson & Johnson's Spravato has been approved to treat a ...